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1,25-Dihydroxyvitamin D3 (1,25D), the hormonal form
of vitamin D, and several analogs have failed as
monotherapies for cancer because of poor efficacy
or acquired resistance. However, 1,25D analogs are
amenable to bifunctionalization. Preclinical studies
have revealed combinatorial effects of 1,25D analogs
and histone deacetylase inhibitors (HDACi). Secos-
teroidal hybrid molecules combining vitamin D re-
ceptor (VDR) agonism with HDACi displayed en-
hanced efficacy but are laborious to synthesize.
Here, we have developed easily assembled, fully
integrated, non-secosteroidal VDR agonist/HDACi
hybrids. The most promising are full VDR agonists
with 10-fold lower potency than 1,25D. Structure/
function studies revealed that antiproliferative
activity against 1,25D-resistant squamous carci-
noma cells required VDR agonism and HDACi.
Remarkably, modeling and X-ray crystallography
reveal non-secosteroidal hybrids bind in the VDR
ligand binding domain in the opposite orientation of
their secosteroidal counterparts.
INTRODUCTION
Vitamin D was identified as the cure for nutritional rickets and is
a critical regulator of calcium homeostasis. However, it is now
considered to have pleiotropic actions, including rapidly growing
evidence for function as a cancer chemopreventive agent and as
a key modulator of immune system function (Deeb et al., 2007;
Lin andWhite, 2004, 2008). These properties are of considerable
clinical significance in light of several studies suggesting that
vitamin D insufficiency and deficiency are widespread globally
(Arabi et al., 2010; Holick, 2007). Vitamin D is converted by
hepatic 25-hydroxylation, followed by 1a-hydroxylation in sev-
eral peripheral tissues into the active metabolite, 1,25-dihydrox-
yvitamin D3 (1,25D; Figure 1). Hormonal 1,25D activates the
vitamin D receptor (VDR), which functions as a ligand-regulatedChemistry & Biology 19, 96transcription factor (Afonja et al., 2004). In a classic negative
feedback loop, 1,25D stimulates its ownmetabolism by inducing
transcription of the gene encoding the CYP24 enzyme essential
for 1,25D catabolism.
The therapeutic potential of 1,25D is limited by its induction of
elevated high circulating calcium concentrations (hypercal-
cemia). A number of 1,25D analogs have been developed that
are non-calcemic while still retaining the potential therapeutic
effects of 1,25D (Eelen et al., 2007). However, these have gener-
ally failed in clinical trials because of poor efficacy or acquired
resistance (Deeb et al., 2007). We have been studying the
capacity of 1,25D, and its analogs, to inhibit proliferation of
head and neck squamous carcinoma cells (HNSCC) (Akutsu
et al., 2001; Lin et al., 2002; Prudencio et al., 2001). Whereas
proliferation of well-differentiated human SCC25 cells is arrested
in G0/G1 (Akutsu et al., 2001), poorly differentiated SCC4 cells
are 1,25D-resistant. However, this resistance can be overcome
by coadministration of the histone deacetylase inhibitor (HDACi)
trichostatin A (TSA). Indeed, SCC4 cells are particularly sensitive
to the combination of 1,25D and TSA, consistent with combina-
tory effects on prostate and breast cancer cell proliferation and
survival (Banwell et al., 2004, 2006; Khanim et al., 2004; Rashid
et al., 2001).
HDACs are a broad family of nuclear or cytoplasmic proteins
that, in combination with histone acetyltransferases (HATs),
control the state of acetylation of several histone and nonhistone
proteins (Venugopal and Evans, 2011; Walkinshaw and Yang,
2008). Nuclear HDACs can modulate gene transcription by
controlling DNA-histone interactions in the nucleosome and
through regulation of components of the transcriptionmachinery.
HDACis, such as TSA and suberoylanilide hydroxamic acid
(SAHA), have been investigated as anticancer agents and, similar
to VDR agonists, HDACs induce cell cycle arrest, cellular
differentiation and/or apoptosis (Kim et al., 2006; McLaughlin
and La Thangue, 2004; Villar-Garea and Esteller, 2004).
Based on the synergistic effects of TSA and 1,25D, we devel-
oped a class of therapeutic agents which are hybrids of 1,25D
and HDACs (Lamblin et al., 2010a; Tavera-Mendoza et al.,
2008). The first molecule in this class, triciferol, merged the se-
costeroidal backbone of 1,25D with a side-chain derived from
TSA. In this design, the terminal hydroxamic acid zinc-binding3–971, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 963
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Figure 1. Structures of VDR Agonists, HDACi, and VDR Agonist/HDACi Hybrids
(A) Structures of 1,25D, HDACis TSA and SAHA, secosteroidal 1,25D/HDACi hybrid triciferol, VDR antaognist ML-3-452, and non-secosteroidal VDR agonist
LG190178.
(B) Structures of novel non-secosteroidal VDR agonist/HDACi hybrids.
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Nonsecosteroidal Vitamin D/HDACi Hybridsgroup (ZBG) critical for HDAC inhibition replaced the 25-hydroxy
end of 1,25D (Tavera-Mendoza et al., 2008). Triciferol is both a
VDR agonist and an HDACi in cells and in culture, and was
more efficacious in vitro than 1,25D in inhibition of SCC4 cell
proliferation. Further studies developed a series of bifunctional
secosteroidal hybrids incorporating variations in side-chain
length and substitution, and a variety of ZBGs targeting HDACs
(Lamblin et al., 2010a). This revealed that the choice of ZBG
could influence HDACi activity and HDAC specificity substan-
tially, with somehybrids inducing histone hyperacetylation (either
H3 or H4, or both) and others inducing tubulin hyperacetylation.
This work also led to the identification of ML 3-452, which is
a strong antagonist due to the combination of its bulky ortho-ami-
noanilide side group and more rigid side-chain (Lamblin et al.,
2010b). A major drawback, however, was that all compounds
were based on the structure of 1,25D, and as such, assembly
of these hybrids all required lengthy synthetic sequences in
excess of 20 steps.964 Chemistry & Biology 19, 963–971, August 24, 2012 ª2012 Elsevi1,25D analog development has largely moved from syn-
thetically challenging secosteroidal backbones to more easily
assembled structures identified in high-throughput screens.
The 3,3-diarylpentanes, as typified by LG190178 (Boehm et al.,
1999; Ma et al., 2006; Swann et al., 2002), are a class of easily
synthesized VDR agonists that display potent prodifferentiation
and antiproliferative effects, while generally lacking calcemic
activity in mice. We sought to synthesize compounds that
combined these synthetically accessible backbones with ZBGs
necessary for HDAC inhibition.
We report here on the design, synthesis, and functional anal-
ysis of several compounds developed in this effort. We have
found that non-secosteroidal VDR agonists are readily amenable
to bifunctionalization, generating compounds that are effica-
cious inhibitors of vitamin D-resistant SCC4 cell proliferation
and survival. Remarkably, and in stark contrast to secosteroidal
hybrids, we find that the hybrid molecules bind in the VDR with
the ZBG occupying the A-ring binding pocket. These studieser Ltd All rights reserved
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Nonsecosteroidal Vitamin D/HDACi Hybridsreveal an unexpected flexibility in our capacity to convert
synthetically accessible vitamin D analogs into fully integrated
bifunctional compounds with enhanced cytostatic/cytotoxic
efficacy. Additionally, this suggests that such a hybrid approach
may be amenable to other combinations of pharmocophores.
RESULTS
Design, Synthesis, and VDR Agonism of Non-
Secosteroidal Hybrids
Our hybrids were designed using the LG190178 skeleton as
a guide. X-ray crystallographic analysis has shown that the
2-hydroxy-3,3-dimethylbutyl group in LG190178 acts as amimic
for the side-chain of 1,25D while the 2,3-dihydroxypropyl group
is a mimic for the A-ring (Hakamata et al., 2008). In our design of
triciferol, we replaced the side-chain of 1,25D with a dienylhy-
droxamic acid and we hypothesized that replacement of the
2-hydroxy-3,3-dimethylbutyl group with an acetic hydroxamic
acid would yield a bifunctional molecule. Thus, initially, we
prepared several hybrids of this form and possessing a
variety of A-ring mimics including the one found in LG190178
(JF-B40, -21, and -52). For comparison, we also prepared a
symmetric bis-hydroxamic acid (JF-B06) and an analog
(JF-B01) where the A-ring mimic was replaced with an acetic-
hydroxamic acid. The synthesis of these analogs was easily
achieved in 5-8 steps by alkylation of a symmetrical diol
prepared by condensation of o-cresol with 3-pentanone under
acidic conditions (see Supplemental Information available
online).
Test compounds (10 mM) were first screened for VDR agonism
by analysis of induction of CYP24 gene expression in 1,25D-
sensitive human SCC25 cells. CYP24 was chosen because its
expression is highly induced and exquisitely sensitive to the
presence of VDR agonists. Quite unexpectedly, only JF-B01
showed any VDR agonist activity (Figure 2A). In contrast,
compounds JF-B21, JF-B40, and JF-B52, all designed using
triciferol as a guide, as well as symmetric JF-B06, were
completely inactive as VDR agonists at 10 mM. JF-B01 is an effi-
cacious agonist, with a potency equal to or greater than that of
LG190178, and approximately 10-fold lower than that of 1,25D
(Figure 2B). The carboxylic acid analog of JF-B01 (JF-C11)
also showed some agonist activity.
With the observation of VDR agonism of hybrids where the
A-ring mimic is replaced with a hydroxamic acid, we prepared
several similar hybrids. These showed that the secondary alcohol
of JF-B01 is clearly important for VDR agonism, as its ketone
derivative (JF-B59) functioned with a >10-fold lower potency
(Figure 2B). Similarly, compounds JF-B53 and JF-B54 also
showed at least partial VDR agonist activity, but with reduced
potency (Figure 2B). They are analogous in structure to JF-B01,
but possess tertiary alcohols more similar to those in the side-
chains of 1,25D and its analog EB1089 (Colston et al., 1992),
respectively. Consistent with binding of hybrids to the VDR,
induction of CYP24 by JF-B01, JF-B53 or JF-B54 was blocked
(Figure 2C) by recently developed VDR antagonist ML 3-452
(Lamblin et al., 2010b). JF-B01 also functioned as a full agonist
of 1,25D target genes IL1RL1, and CAMP (Lin et al., 2002;
Wang et al., 2004), whereas it consistently superinduced ex-
pression of GADD45 (Figure S1), in agreement with combinedChemistry & Biology 19, 96effects of VDR agonists and TSA on GADD45 expression seen
in other studies (Banwell et al., 2004; Khanim et al., 2004).
Lead compound JF-B01 was initially prepared in racemic
form. However, its VDR agonism, along with the knowledge
that the 20R isomer of LG190178 is the more active form (Haka-
mata et al., 2008), prompted preparation of enantioenriched
forms. This was easily accomplished by reduction of the corre-
sponding ketone using the Corey oxazaborolidine catalysts
(Corey et al., 1987a, 1987b), to afford the (R)- and (S)-isomers,
JF-C71 and JF-C72 respectively, each in >95% ee (see Supple-
mental Information). Both enantiomers proved to be VDR
agonists with similar potencies (Figure 2D), suggesting that the
side-chain can adopt multiple binding conformations in the
VDR ligand binding pocket. Moreover, both enantiomers
induced binding of the VDR to the vitamin D response element
located in the proximal promoter of the CYP24 gene, as as-
sessed by chromatin immunoprecipitation (ChIP) assay (Fig-
ure 2E), consistent with their function as VDR agonists. Direct
binding to the VDR of the most potent hybrids JF-C71 and
-C72 was confirmed by a fluorescence polarization competition
assay (Tavera-Mendoza et al., 2008). JF-C71 and -C72 com-
peted for binding with an IC50 of approximately 100 and 35 nM
(Figure 2F), respectively, or less than one order of magnitude
lower than the 13 nM IC50 of 1,25D in this assay (Tavera-Men-
doza et al., 2008), and in excellent agreement with studies of
VDR agonism above. Taken together, VDR agonist activities
and structures of JF-B01, JF-B53, and JF-B54, along with those
of inactive compounds, suggest, surprisingly, that the hydroxa-
mic acid moiety is a viable surrogate for the A-ring of 1,25D.
The above structure/function studies were strongly supported
by the results of molecular modeling. We used FITTED, a
program which proved useful for the design of triciferol, for
our studies. Using the protein structure of rat VDR bound
to LG190178 (Hakamata et al., 2008), we docked the
(R)-enantiomer JF-C71 and the (2S,20R)-enantiomer of JF-B40
and compared them to the (2S,20R)-enantiomer of LG190178
(Figure 3A). Notably, both hybrids docked with the hydroxamic
acid in the A-ring binding pocket (Figure 3A, i and ii) despite
the large difference in the second substituents. The hydroxamic
acid of JF-C71 made significant hydrogen bond contacts to
Arg270, Tyr143, and Ser274, while JF-B40 made close contact
with Arg270 and Ser233. Of the two, the hydroxamic acid
JF-B40 more closely resembled the conformation of the diol
in LG190178 (Figure 3A, iii and iv). Importantly, the overall
orientation puts the polar diol of JF-B40 in the side-chain
binding pocket. This forcing of the diol into the side-chain
pocket is presumably responsible for the poorer binding score
observed in FITTED and its lack of activity described above.
Importantly, while the secondary alcohol makes a similar
hydrogen bond contact with His301 as LG190178, the primary
alcohol docks in the same location as the hydrophobic tert-
butyl group (Figure 3A, iv). This mismatch is presumably the
most significant factor in the loss of activity of JF-B40 and
related hybrids.
Crystal Structure of JF-C71 and JF-C72 Bound to the
Zebrafish-VDR Ligand Binding Domain
The modeling data above were substantially corroborated
by crystal structures of JF-C71 and JF-C72 bound to the3–971, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 965
Figure 2. Identification and Characterization of Non-Secosteroidal VDR Agonists
(A) Initial screening by RT/qPCR for induction of CYP24 expression in SCC25 cells by JF-B01, -B06, -B21, -B40, and -B52 (10 mM).
(B) Dose-dependent CYP24 induction by JF-B01, -B04, -B11, -B53, -B54, and -B59, along with 1,25D as a positive control.
(C) CYP24 expression induced by JF-B01 (1 mM), or -B53 and -B54 (10 mM) is inhibited by VDR antagonist ML-3-452 (3; 10 mM). See also Figure S1A.
(D) Enantiomers of JF-B01, JF-C71 and -C72, are agonists of the VDR as measured by CYP24 induction.
(E) JF-B01, -C71, and -C72 (1 mM) induce DNA binding of the VDR to the proximal promoter region of the CYP24 promoter as measured by chromatin immu-
noprecipitation (ChIP) assay.
(F) JF-C71 and -C72 compete for binding of a fluorescent tracer to the VDR ligand binding domain with apparent IC50 of 100 and 35 nM, respectively, asmeasured
by fluorescence polarization assay.
Error bars represent SEM.
Chemistry & Biology
Nonsecosteroidal Vitamin D/HDACi Hybridszebrafish-VDR (zVDR) LBD, solved at a resolution of 2.4 and
2.33 A˚, respectively (see Figure 3B, i and ii; Supplemental
Information; and Table S1 for details). Note that the human-,
rat-, and zebrafish-VDR ligand binding pockets are lined with
identical residues and have homologous structures (Ciesielski
et al., 2007). Both complexes display the canonical agonist
conformation of all previously reported structures of VDR bound
to agonist and superagonist ligands with helix H12 folded in the
agonistic position (Antony et al., 2010; Ciesielski et al., 2007;966 Chemistry & Biology 19, 963–971, August 24, 2012 ª2012 ElseviRochel and Moras, 2006). When compared to the zVDR LBD-
1,25D structure, the Ca atoms of the zVDR LBD-JF-C71 and
zVDR LBD-JF-C72 complexes have a root mean square devia-
tion (rmsd) of 0.382 and 0.386 A˚, respectively over 248 residues.
The ligands are buried in the predominantly hydrophobic pocket
and adopt the same orientation as YR301, the (2S,20R)-
stereoisomer of LG190178 (Figure 3B, iii; Kakuda et al., 2008).
The diethyl groups occupy the space filled by the CD-rings of
the natural 1,25D ligand. JF-C71 and JF-C72 form similarer Ltd All rights reserved
Figure 3. Modeling and X-Ray Structural
Data
(A) Structures obtained from docking of ligands to
VDR (PDB file 2ZFX) with helix 6 deleted for clarity.
Docking solutions of (i) JF-B01 and (ii) JF-B40 in
VDR indicating the binding of the hydroxamic acid
in the A-ring binding pocket. Note that pro-
tein chain between amino acids 284–291 has
been removed for clarity. Overlays of (iii) JF-B01
(orange) and (iv) JF-B40 (yellow) with LG190178
(blue) showing the correlation of the hydroxamic
acid in JF-B01 with the diol of LG190178 and the
placement of the 2-OH group of JF-B40 in the
same space as a methyl group in LG190178.
(B) X-ray crystallographic structures of (i) JF-C71
and (ii) JF-C72 bound to zVDR LBD. (iii) Overlay of
JF-C71 (orange) with YR-301 (blue), the (2S,20R)-
stereoisomer of LG190178, showing excellent
correlation of binding conformation. (iv) Overlay
of JF-C71 (orange) with JF-C72 (green) showing
minor conformational changes at the C2-OH
group.
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Nonsecosteroidal Vitamin D/HDACi Hybridsinteractions with the zVDR ligand binding pocket with the
hydroxamate groups pointing toward helix H1 of the zVDR
LBD and occupying the 1,25D A-ring binding pocket. The
hydroxamic acid side-chain adopts a conformation slightly dif-
ferent than that predicted by the modeling. The hydroxy group
interacts through an H-bond with Arg302 (2.6 A˚ for JF-C71,
3.0 A˚ for JF-C72). This interaction directly mimics that of the
C1-OH of 1,25D in the LBP (Ciesielski et al., 2007). In addition,
the NH forms a hydrogen bond with Ser265 (2.5–2.6 A˚). This
hydroxamic acid conformation was predicted in the modeling
above for JF-B40 but not for JF-C71 where the hydroxamate
OH adopted a similar position to C3-OH in 1,25D. Given the
polarity of the binding pockets for both C1-OH and C3-OH in
1,25D, this minor discrepancy between modeling and X-ray
data was not surprising. Van der Waals interactions of the OH
and carbonyl group are observed with Tyr264, Arg302, and
Tyr175. Those residues are also interacting with water molecules
forming thewater channel that was previously described near the
C2 position of 1,25D. Due to the inverse configuration of the
alcohol at C20, the stereoisomers adopt slightly different side-
chain conformations (Figure 3B, iv) that result in a similar posi-
tion of the hydroxyl group interacting through hydrogen bonds
with His333 and His423 (distances of interactions of 2.6 A˚ and
3.0 A˚ for JF-C71, and 2.7 A˚ and 3.2 A˚ for JF-C72). Taken together,
the above structural studies demonstrate that the hydroxamic
acid moiety is a viable surrogate for the A-ring of 1,25D, andChemistry & Biology 19, 963–971, August 24, 2012confirm the remarkable structural flexi-
bility in conversion of 1,25D analogs into
fully integrated bifunctional molecules.
HDACi Activities of Test
Compounds
Several of the compounds developed
above were initially tested for their
capacity to inhibit purified class I
HDAC3 and class II enzyme HDAC6
in vitro (Wegener et al., 2003a, 2003b)using SAHA as a positive control. Compounds tested inhibited
HDAC3 in vitro with IC50 values between 13 and 36 mM, which
compares very favorably with the IC50 of triciferol for this enzyme
(13.3 mM; Lamblin et al., 2010a), but about 500- to 1000-fold
lower than that of SAHA (Table 1). With the exception of JF-
B06, IC50 values for inhibition of HDAC6 in vitro were in a very
similar range at around 30 mM, or 50-fold lower than SAHA.
JF-B06, unlike other compounds, is flanked by dual hydroxamic
ZBGs and displayed an approximate 10-fold improved potency
for HDAC6 (4.7 mM). Finally, we assessed JF-C71 for its activity
against HDAC1 and HDAC2, where it showed 14.3 mM and
6.0 mM potency, respectively. Thus these hybrids appear to be
effective against a range of HDACs.
Several VDR agonists aswell as JF-B40, whichwas inactive as
an agonist, were also tested along with 1,25D for HDACi activity
using a fluorogenic substrate in vivo (Ciossek et al., 2008) in
SCC25 andSCC4cells (Figures 4A and4B). This assaymeasures
the inhibition of total intracellular HDAC activity and determines
the capacity of compounds to inhibit HDACs in the form of their
naturally occurring complexes. While an increasing concentra-
tion of 1,25D had no effect on substrate deacetylation in either
cell line, all compounds tested displayed dose-dependent
HDAC inhibition, with JF-B54 being the most potent. Notably,
unlike 1,25D, JF-B01, -C71, and -C72 also induced histone H3
acetylation on the CYP24 promoter as assessed by ChIP assay,
which is consistent with their HDACi activity (Figure S2).ª2012 Elsevier Ltd All rights reserved 967
Table 1. HDACi Activity of Selected Compounds Determined
Using a Standard Fluorescence Assay against Purified HDACs
Compound HDAC3 HDAC6
SAHA 33.8 nM 580 nM
JF-B06 13.4 mM 4.7 mM
JF-B21 36.1 mM 37.9 mM
JF-B53 17.0 mM 33.3 mM
JF-B54 29.9 mM 31.5 mM
JF-C71 22.0 mM 26.1 mM
HDAC1 HDAC2
SAHA 287 nM 516 nM
JF-C71 14.3 mM 6.0 mM
Purified HDACs were obtained from Cayman Chemical. See Wegener
et al., 2003a and 2003b.
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Nonsecosteroidal Vitamin D/HDACi HybridsCytostatic/Cytotoxic Activities of Bifunctional
Compounds
JF-B01, JF-B53, and JF-B54 were further tested for their
capacity to inhibit the proliferation of 1,25D-sensitive (SCC25
and AT84) or 1,25D-resistant (SCC4) HNSCC lines. As expected
(Akutsu et al., 2001; Lin et al., 2002; Prudencio et al., 2001),
proliferation of SCC25 or AT84 cells was strongly inhibited by
1,25D (Figures 4C and 4D), as measured by incorporation of
the nucleoside analog EdU. All test compounds blocked EdU
incorporation with relative potencies that were roughly parallel
to their capacity to induce CYP24 expression. JF-B01 was
10-fold less potent than 1,25D in these assays. JF-B06 and
JF-B21, which possess HDACi activity but are devoid of VDR
agonism, failed to block AT84 proliferation (Figure 4D). Remark-
ably, whereas SCC4 cell proliferation was resistant to 1,25D, it
was found that JF-B01, JF-B53, or JF-B54 partially or totally
blocked EdU incorporation (Figure 4E; Figure S3). Significantly,
LG190178 and JF-C11, the carboxylic acid analog of JF-B01
which displays VDR agonism, and HDACi JF-B21 all failed to
block SCC4 proliferation (Figure S4), consistent with the efficacy
of JF-B01 being dependent on both VDR agonist and HDACi
activity. It is also noteworthy that, unlike 1,25D, hybrid com-
pounds completely abolished EdU incorporation in SCC25 cells
and in SCC4 cells at higher concentrations. Corresponding
plates treated with compounds were free of cells after 48h of
treatment, consistent with dose-dependent reduction in live cells
as measured by a fluorescence-based cytotoxicity assay (Fig-
ure 4F) or by liberation of lactate dehydrogenase activity from
dying cells (Figure S5). Death appeared to occur by apoptosis,
as, like positive control staurosporin, hybrid compounds induced
substantial levels of apoptosis-associated caspase activity (Fig-
ure S6; data not shown). Finally, JF-B01 was assessed by the
National Cancer Institute in their 60 cell panel of human carci-
noma cell lines. It displayed antiproliferative activity in all cell
lines, with the most promising results in melanoma cell lines
with full growth inhibition at 7 mM or less in eight out of nine
cell lines (see Supplemental Information; Figure S7).
DISCUSSION
In our original work, we developed triciferol, designed to
combine nuclear receptor agonismwith HDACi activity in a single968 Chemistry & Biology 19, 963–971, August 24, 2012 ª2012 Elsevistable (i.e., non-prodrug) entity (Tavera-Mendoza et al., 2008).
While this molecule provided excellent proof-of-principle for
the concept and possessed enhanced cytostatic and cytotoxic
activity, its lengthy synthesis beginning from ozonolytic degrada-
tion of vitamin D2 made analog development laborious and
expensive and limited significant variation to mainly the side-
chain. The non-secosteroidal hybrids described herein have
several advantages. They are easily prepared in 5–10 steps
from inexpensive starting materials. In addition, because they
differ structurally from 1,25D, they are very likely to be resistant
to catabolism by CYP24 activity, which is strongly induced by
VDR agonists. The most promising of these novel hybrids,
JF-B01 and its enantioenriched forms JF-C71 and JF-C72 are
at least as efficacious as 1,25D in inducing VDR DNA binding
as assessed by ChIP assay, in stimulating CYP24 gene tran-
scription, and they induce CYP24 expression with a potency of
10-fold lower than that of 1,25D. This profile is highly compa-
rable to the VDR agonist activity observed for triciferol (Tavera-
Mendoza et al., 2008). While the potencies of non-secosteroidal
compounds as HDAC6 inhibitors are reduced by about one
order of magnitude relative to triciferol and other secosteroidal
hybrids (Lamblin et al., 2010a; Tavera-Mendoza et al., 2008),
their HDAC3i activity in vitro is essentially the same.
Comparative studies in 1,25D-sensitive and 1,25D-resistant
HNSCC lines provided several insights into the biochemical
activities required for antiproliferative activity. JF-B01 inhibited
proliferation of 1,25D-sensititve SCC25 and AT84 cells about
10-fold less potently than 1,25D. However, JF-B06 and JF-B21,
which possess HDACi activity, but are not VDR agonists, were
devoid of activity in this assay. JF-B21 was also inactive against
1,25D-resistant SCC4 cells, suggesting that HDAC inhibition on
its own does not afford cytostatic activity in this assay. Similarly,
JF-C11, the precursor of JF-B01 which is a VDR agonist but
lacks a ZBG, and the parent compound LG190178 were inactive
against SCC4 cells. These data strongly argue that the cytostatic
efficacy of hybrids JF-B01, -B53 and -B54 in SCC4 cells stems
from their specific combination of both VDR agonism and HDACi
activity. In addition, the gain of function in these hybrids appar-
ently does not require potency for HDAC inhibition to be in the
nanomolar range: all three hybrids are 50–1000 times less potent
than SAHA in in vitro assays yet function effectively in cells.
A surprising revelation of these studies was that hybrids were
active as VDR agonists only when the A-ring mimic diol of
LG190178 was replaced with a hydroxamic acid. This observa-
tion was strongly supported by docking studies in the human
VDR, which placed the hydroxamic acid in the A-ring binding
pocket and confirmed by X-ray crystallography of JF-C71 and
JF-C72 bound to the zebrafish-VDR. JF-C71 and JF-C72 form
similar interactions with the zVDR LBD with the hydroxamate
groups pointing toward the end of helix H1. The stereoisomers
adopt different side-chain conformations that result in a similar
position of the hydroxyl group interacting through hydrogen
bonds with His333 and His423. These findings stand in sharp
contrast to both triciferol and its analogs where the ZBG takes
the place of the C25-OH in 1,25D, and highlights the remarkably
high synthetic latitude in creating hybrid VDR agonist/HDACi
hybrids.
Part of this flexibility arises from the structural latitude avail-
able in the generation of HDACis. HDACis are composed ofer Ltd All rights reserved
Figure 4. HDACi and Cytostatic Activities of Hybrid Compounds
(A and B) HDACi activity of compounds wasmeasured in live SCC25 or SCC4 cells, as indicated, as described in Supplemental Experimental Procedures. HDACi
activity of non-secosteroidal compounds wasmeasured in 10-fold increments between 1nM (1) and 10 mM (5), whereas 1,25Dwas tested between 0.1 nM (1) and
1 mM (5). See also Figure S2.
(C–E) The dose-dependent antiproliferative activities of 1,25D or non-secosteroidal compounds were assessed by measuring incorporation of fluorescent
nucleoside analog EdU in 1,25D-sensitive SCC25 cells (C), or AT84 cells (D), or 1,25D-resistant SCC4 cells (E). See also Figures S3 and S4.
(F) Measurement of SCC4 or SCC25 viability in the presence of increasing concentrations of 1,25D or hybrid molecules indicated (Supplemental Experimental
Procedures). See also Figures S5 and S6.
Error bars represent SEM.
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Nonsecosteroidal Vitamin D/HDACi HybridsZBGs fused to linkers coupled to so-called cap groups, which
can be highly heterogeneous in structure, ranging from derivat-
ized aromatic rings (e.g., SAHA) to cyclic peptides (Paris
et al., 2008; Villar-Garea and Esteller, 2004). In the molecules
developed here, the derivatized 3,3-diarylpentane would serve
as both side-chain and cap group. However, the finding that, de-
pending on the hybrid, the ZBG can either occupy A-ring binding
site of the VDR ligand binding domain as in the non-secosteroi-
dal hybrids described here, or replace the 25-OH group of 1,25DChemistry & Biology 19, 96as found for triciferol and its analogs, was unexpected. This
suggests therefore that there remains substantial latitude for
structure-guided optimization of the potencies of both the VDR
agonist and HDACi activities of hybrids. It also suggests that it
is reasonable to expect that other classes of drugs can be
bifunctionalized. Although bifunctionalization would likely lead
to a loss of potency for the primary target, addition of activity
against a second, sympathetic biochemical target would be
expected to increase clinical efficacy.3–971, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 969
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The active formof vitaminD, 1,25-dihydroxyvitaminD (1,25D)
has attracted broad interest because of its anticancer prop-
erties and its potential as a chemopreventive agent.
However, 1,25D and several analogs have failed as cancer
therapies because of poor efficacy or acquired resistance.
Previous work has shown that 1,25D/HDACi hybrids in
which zinc-binding groups necessary for HDACi replaced
the 25-hydroxy terminus of the 1,25D secosteroid are
more effacious than 1,25D against numerous cancer cell
lines, including 1,25D-resistant cell lines. These hybrids
are remarkable, as HDACi activity was fully integrated into
the secosteroidal backbone of a VDR agonist. However,
the secosteroidal nature of the hybrids severely limited
their synthetic accessibility. Here, we have shown that it
is possible to create easily assembled non-secosteroid-
based hybrids that function efficaciously as both VDR
agonists and HDACis. Moreover, our studies show that,
contrary to secosteroidal hybrids, the optimal location for
incorporating the highly hydrophilic hydroxamic acid corre-
sponds to the portion of the molecules that serve as secos-
teroidal A-ring mimetics. The best hybrid, JF-B01, is a full
VDR agonist as assessed by several criteria, and an effica-
cious antiproliferative agent against both 1,25D-sensitive
(SCC25, AT84) and 1,25D-resistant (SCC4) squamous
carcinoma cell lines. Importantly, activity in 1,25D-resistant
SCC4 cells required both the VDR agonism and HDACi
activity of JF-B01. Furthermore, profiling by the NCI in a
60-cell line screen revealed it to be active against a wide-
range of cancer cell lines, including melanoma where it
displayed full growth inhibition at low micromolar con-
centrations in eight out of nine cell lines. Finally, in con-
junction with previous studies on secosteroidal hybrids,
the work presented here reveals the remarkable flex-
ibility in conversion of 1,25D analogs into fully integrated
bifunctional molecules, suggesting that it may be possible
to extend fully integrated bifunctionalization to other
pharmacophores.
EXPERIMENTAL PROCEDURES
All details about the Experimental Procedures used are given in the Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2012.05.024.
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